100 related articles for article (PubMed ID: 7735216)
21. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
Wild C; Oas T; McDanal C; Bolognesi D; Matthews T
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10537-41. PubMed ID: 1438243
[TBL] [Abstract][Full Text] [Related]
22. Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers.
Zhang L; Scott MG; Yan H; Mayer LD; Hancock RE
Biochemistry; 2000 Nov; 39(47):14504-14. PubMed ID: 11087404
[TBL] [Abstract][Full Text] [Related]
23. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
Wild CT; Shugars DC; Greenwell TK; McDanal CB; Matthews TJ
Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9770-4. PubMed ID: 7937889
[TBL] [Abstract][Full Text] [Related]
24. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ; Lambert DM; Tompkins WA
J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
[TBL] [Abstract][Full Text] [Related]
25. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Chong H; Zhu Y; Yu D; He Y
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death.
Callebaut C; Jacotot E; Guichard G; Krust B; Rey-Cuille M; Cointe D; Benkirane N; Blanco J; Muller S; Briand J; Hovanessian AG
Virology; 1996 Apr; 218(1):181-92. PubMed ID: 8615021
[TBL] [Abstract][Full Text] [Related]
27. The inhibitory effect of the crude extract from a seaweed of Dygenea simplex C. Agardh on the in vitro cytopathic activity of HIV-1 and it's antigen production.
Sekine H; Ohonuki N; Sadamasu K; Monma K; Kudoh Y; Nakamura H; Okada Y; Okuyama T
Chem Pharm Bull (Tokyo); 1995 Sep; 43(9):1580-4. PubMed ID: 7586085
[TBL] [Abstract][Full Text] [Related]
28. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
[TBL] [Abstract][Full Text] [Related]
29. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.
Benjouad A; Chapuis F; Fenouillet E; Gluckman JC
Virology; 1995 Jan; 206(1):457-64. PubMed ID: 7831801
[TBL] [Abstract][Full Text] [Related]
30. Effects of tubeimoside-1 on HIV core protein p24 and cytopathogenesis in vitro.
Yu LJ; Ma RD; Jiang SB
Zhongguo Yao Li Xue Bao; 1994 Mar; 15(2):103-6. PubMed ID: 8010099
[TBL] [Abstract][Full Text] [Related]
31. Anti-HIV agents II. Synthesis and in vitro anti-HIV activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles.
Chimirri A; Grasso S; Monforte AM; Monforte P; Zappala M
Farmaco; 1991; 46(7-8):925-33. PubMed ID: 1686551
[TBL] [Abstract][Full Text] [Related]
32. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II.
Luo Z; Fan X; Zhou N; Hiraoka M; Luo J; Kaji H; Huang Z
Biochemistry; 2000 Nov; 39(44):13545-50. PubMed ID: 11063591
[TBL] [Abstract][Full Text] [Related]
33. Differential contribution of metal complexation and dimerization to the chemotherapeutic potential of bicyclen-Zn2II complex against human immunodeficiency virus.
Inouye Y; Kanamori T; Yoshida T; Koike T; Shionoya M; Fujioka H; Kimura E
Biol Pharm Bull; 1996 Mar; 19(3):456-8. PubMed ID: 8924918
[TBL] [Abstract][Full Text] [Related]
34. Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
Mabrouk K; Van Rietschoten J; Rochat H; Loret EP
Biochemistry; 1995 Jul; 34(26):8294-8. PubMed ID: 7599121
[TBL] [Abstract][Full Text] [Related]
35. In vitro assessment of compounds for anti-HIV activity.
Patience C; Moore J; Boyd M
Mol Biotechnol; 1994 Feb; 1(1):49-58. PubMed ID: 7532100
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and activity evaluation of novel peptide fusion inhibitors targeting HIV-1 gp41.
Tan J; Su M; Zeng Y; Wang C
Bioorg Med Chem; 2016 Jan; 24(2):201-6. PubMed ID: 26706116
[TBL] [Abstract][Full Text] [Related]
37. Antiviral action of oligodeoxyguanylic acids against human immunodeficiency virus type 1.
Fujihashi T; Sakata T; Kaji A; Kaji H
AIDS Res Hum Retroviruses; 1995 Apr; 11(4):461-71. PubMed ID: 7543270
[TBL] [Abstract][Full Text] [Related]
38. Antimyristoylation of GAG proteins in human T-cell lymphotropic and human immunodeficiency viruses by N-myristoyl glycinal diethylacetal.
Shoji S; Tashiro A; Kubota Y
Ann N Y Acad Sci; 1990; 616():97-115. PubMed ID: 1706577
[No Abstract] [Full Text] [Related]
39. Anti-HIV agents. I: Synthesis and in vitro anti-HIV evaluation of novel 1H,3H-thiazolo[3,4-a]benzimidazoles.
Chimirri A; Grasso S; Monforte AM; Monforte P; Zappalà M
Farmaco; 1991 Jun; 46(6):817-23. PubMed ID: 1685321
[TBL] [Abstract][Full Text] [Related]
40. Photoactive terthiophenes: the influence of serum on anti-HIV (human immunodeficiency virus) activities.
Hudson JB; Marles RJ; Soucy-Breau C; Harris L; Arnason JT
Photochem Photobiol; 1994 Dec; 60(6):591-3. PubMed ID: 7870765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
